While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related ...

Cassava Sciences has officially ended development of simufilam in Alzheimer’s disease, marking the end of a tumultuous era ...

If you’ve ever watched Shark Tank, you probably know Barbara Corcoran. On the show, she invests in businesses, but away from ...

NEW YORK (Reuters) -The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's diseaseSimufilam continued to dem ...

Washington University-led research shows a small group of participants in an Alzheimer’s study experienced a significant ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Cassava Sciences (NASDAQ:SAVA) lost ~19% in the premarket on Tuesday after the company announced plans to discontinue its ...